Clinical trials are on the way using FXR modulators in chronic liver diseases such as primary biliary cholangitis, in cholestasis, nonalcoholic steatohepatitis (NASH), obesity, metabolic syndrome, hypertriglyceridemia, lipodystrophy. The gene discussed is NR1H4; the disease is metabolic syndrome.